These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28289033)

  • 1. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
    Alsultan A; Savic R; Dooley KE; Weiner M; Whitworth W; Mac Kenzie WR; Peloquin CA;
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
    Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
    Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
    Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.
    Naftalin CM; Verma R; Gurumurthy M; Lu Q; Zimmerman M; Yeo BCM; Tan KH; Lin W; Yu B; Dartois V; Paton NI
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.
    Lanoix JP; Tasneen R; O'Brien P; Sarathy J; Safi H; Pinn M; Alland D; Dartois V; Nuermberger E
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4197-205. PubMed ID: 27139472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.
    Hoffner S; Angeby K; Sturegård E; Jönsson B; Johansson A; Sellin M; Werngren J
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1486-90. PubMed ID: 24125455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
    Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
    Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
    Egelund EF; Isaza R; Brock AP; Alsultan A; An G; Peloquin CA
    J Vet Pharmacol Ther; 2015 Apr; 38(2):137-43. PubMed ID: 25236765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
    Yee DP; Menzies D; Brassard P
    Int J Tuberc Lung Dis; 2012 May; 16(5):604-9. PubMed ID: 22409887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.
    Gumbo T; Dona CS; Meek C; Leff R
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3197-204. PubMed ID: 19451303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
    Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH
    Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
    Ngabonziza JCS; Diallo AB; Tagliani E; Diarra B; Kadanga AE; Togo ACG; Thiam A; de Rijk WB; Alagna R; Houeto S; Ba F; Dagnra AY; Ivan E; Affolabi D; Schwoebel V; Trebucq A; de Jong BC; Rigouts L; Daneau G;
    PLoS One; 2017; 12(10):e0187211. PubMed ID: 29088294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.
    Sahota T; Della Pasqua O
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5442-9. PubMed ID: 22777045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
    Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
    Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
    Stehr M; Elamin AA; Singh M
    Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitriol enhances pyrazinamide treatment of murine tuberculosis.
    Zhang J; Guo M; Huang ZX; Bao R; Yu Q; Dai M; Wang X; Rao Y
    Chin Med J (Engl); 2019 Sep; 132(17):2089-2095. PubMed ID: 31425356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review.
    Chen RH; Michael T; Kuhlin J; Schön T; Stocker S; Alffenaar JC
    Int J Antimicrob Agents; 2023 Sep; 62(3):106914. PubMed ID: 37419292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
    Gopal P; Grüber G; Dartois V; Dick T
    Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.